to the editor: Dragun et al. (Feb. 10 issue) 1 provide provocative data on the role of agonistic angiotensin II type 1 (AT 1 )-receptor antibodies in patients with steroid-refractory renal-allograft rejection. We were surprised by the high incidence of biopsy-proved acute rejection among their patients (43 percent), which contrasts with the 15 percent previously reported with a similar immunosuppressive protocol. 2, 3 In addition, 16 of the 33 patients with steroid-refractory rejection in the study by Dragun et al. appeared to have malignant hypertension. The median blood pressure was 153/80 mm Hg in the 10 most recent patients with steroidrefractory rejection in our medical center, only 1 of whom had signs of hypertensive encephalopathy. Finally, information about the original renal disease of the patients is lacking -a relevant point because the AT 1 -receptor antibodies were probably preexistent. We recently observed that patients who had the hemolytic-uremic syndrome are prone to have vascular rejection. 4 Moreover, AT 1 -receptor antibodies have been described in other microangiopathic conditions, such as preeclampsia and malignant hypertension. 5 We propose that the combination of vascular rejection and AT 1 -receptor antibodies occurs particularly in patients who have the hemolytic-uremic syndrome or malignant hypertension as their original renal disease. to the editor: The incidence of severe hypertension after renal transplantation is primarily related to the presence of malignant hypertension in the pretransplantation period. 1 The original disease influences the outcome of kidney transplantation; in particular, recipients with malignant hypertension have poorer graft survival. 2 No information, however, is provided in the article by Dragun et al. about the original cause of end-stage renal disease, posttransplantation antihypertensive medication, or mean blood pressure before and after transplantation. Such data would be important, since hypertension was the sole clinical factor discriminating between the two groups. It was unclear in the paper by Dragun et al. whether this entity represents a subtype of acute rejection or recurrent disease. Preformed AT 1 -receptor antibodies must have been present at the time of transplantation in at least some patients in whom clinical events occurred within days after transplantation. The failure to identify low levels of anti-HLA antibodies with sensitive solid-phase assays 3,4 as well as levels of antibodies that are non-donor-specific 5 may have affected both the accuracy of the subsequent analysis and the conclusions, which were dependent on the stratification of patients according to these criteria. 
